• Home
  • Search Results
  • Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Clinical chemistry (2002-08-27)
Jerry A Katzmann, Raynell J Clark, Roshini S Abraham, Sandra Bryant, James F Lymp, Arthur R Bradwell, Robert A Kyle
ABSTRACT

The detection of monoclonal free light chains (FLCs) is an important diagnostic aid for a variety of monoclonal gammopathies and is especially important in light-chain diseases, such as light-chain myeloma, primary systemic amyloidosis, and light-chain-deposition disease. These diseases are more prevalent in the elderly, and assays to detect and quantify abnormal amounts of FLCs require reference intervals that include elderly donors. We used an automated immunoassay for FLCs and sera from a population 21-90 years of age. We used the calculated reference and diagnostic intervals to compare FLC results with those obtained by immunofixation (IFE) to detect low concentrations of monoclonal kappa and lambda FLCs in the sera of patients with monoclonal gammopathies. Serum kappa and lambda FLCs increased with population age, with an apparent change for those >80 years. This trend was lost when the FLC concentration was normalized to cystatin C concentration. The ratio of kappa FLC to lambda FLC (FLC K/L) did not exhibit an age-dependent trend. The diagnostic interval for FLC K/L was 0.26-1.65. The 95% reference interval for kappa FLC was 3.3-19.4 mg/L, and that for lambda FLC was 5.7-26.3 mg/L. Detection and quantification of monoclonal FLCs by nephelometry were more sensitive than IFE in serum samples from patients with primary systemic amyloidosis and light-chain-deposition disease. Reference and diagnostic intervals for serum FLCs have been developed for use with a new, automated immunoassay that makes the detection and quantification of monoclonal FLCs easier and more sensitive than with current methods. The serum FLC assay complements IFE and allows quantification of FLCs in light-chain-disease patients who have no detectable serum or urine M-spike.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lambda Light Chains (Free) from human myeloma sera, purified immunoglobulin, ~1.0 mg/mL, ≥99% (electrophoresis), buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-Human Lambda Light Chains (Bound and Free) antibody produced in mouse, clone HP-6054, ascites fluid
Sigma-Aldrich
Anti-Human Lambda Light Chain (Bound and Free) antibody produced in rabbit, whole antiserum
Sigma-Aldrich
Anti-Human Lambda Light Chain (Bound and Free) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-Rat Lambda Light Chains antibody produced in mouse, clone RL-6, ascites fluid

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.